IgD multiple myeloma. Review of 133 cases

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Multiple myeloma is a malignant proliferation of plasma cells.
• Immunoglobulin D (IgD) myeloma is a rare subtype, accounting for 2.1% of all myeloma cases.
• Understanding the unique characteristics of IgD myeloma is crucial for diagnosis and treatment.

Purpose of the Study:

• To describe the clinical characteristics, laboratory findings, and survival outcomes of IgD myeloma.
• To compare IgD myeloma with other myeloma subtypes (IgG and IgA).
• To investigate the relationship between M-component type and clinical presentation in multiple myeloma.

Main Methods:

• Retrospective analysis of 133 patients diagnosed with IgD myeloma.
• Review of clinical data including demographics, physical examination findings, laboratory results, and survival data.
• Analysis of M-component type, light chain type, and Bence Jones protein presence.

Main Results:

• IgD myeloma predominantly affects males, with 65% diagnosed before age 60.
• Common findings include lymphadenopathy, hepatomegaly, splenomegaly, severe anemia, and azotemia.
• Lambda light chains are predominant (90%), and Bence Jones proteinuria is nearly universal.
• Mean survival is 13.7 months, shorter than other myeloma types.

Conclusions:

• IgD myeloma exhibits distinct clinical and laboratory features compared to IgG and IgA myeloma.
• The type of M-component may influence the clinical course of multiple myeloma.
• Early recognition and further research into IgD myeloma are warranted.